Clinical efficacy and safety of telmisartan 80 mg once daily vs. atenolol 50 mg once daily in patients with mild-to-moderate hypertension

International Journal of Clinical Practice, Supplement

Volumn , Issue 145, 2004, Pages 35-39

  Alcocer, Luis ^a,e   Fernandez Bonetti P ^b   Campos, E ^a   Olvera Ruiz, R ^c   Bahena, J ^d   De La Fuente, J J ^d   Segovia Ayala, C ^d   Dominguez Henkel, R ^a  

^a HOSPITAL GENERAL DE MÉXICO   (Mexico)

^b Cardiology Service   (Mexico)

^c INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^d HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^e Circuito Fuentes de Pedregal   (Mexico)

Author keywords

Angiotensin II receptor blocker; Antihypertensives; Atenolol; Beta blocker; Hypertension; Telmisartan

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PLACEBO; TELMISARTAN;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; ASTHENIA; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EARLY DIAGNOSIS; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPERTENSION; HYPOTENSION; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 10344251467     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003; 289: 2560-72.
2. Dusing R. Adverse events, compliance, and changes in therapy. Curr Hypertens Rep 2001; 3: 488-92.
3. Frishman WH, Alwarshetty M. Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines. Clin Pharmacokinet 2002; 41: 505-16.
4. Nelson EB, Pool JL, Taylor AA. Pharmacology of angiotensin converting enzyme inhibitors. A review. Am J Med 1986; 81: 13-8.
5. Nicholls MG, Charles CJ, Crozier IG, et al. Blockade of the renin-angiotensin system. J Hypertens 1994; 12 (Suppl. 10): S95-S103.
6. Carr AA, Prisant LM. Losartan: first of a new class of angiotensin antagonists for the management of hypertension. J Clin Pharmacol 1996; 36: 3-12.
7. Wienen W, Entzeroth M, van Meel JCA, et al. A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. Cardiovasc Drug Rep 2000; 18: 127-56.
8. Burnier M, Maillard M. The comparative pharmacology of angiotensin II receptor antagonists. Blood Press 2001; 10 (Suppl. 1): 6-11.
9. Prichard BN, Graham BR, Cruickshank JM. New approaches to the uses of beta blocking drugs in hypertension. J Hum Hypertens 2000; 14 (Suppl. 1): S63-S68.
10. Anderton JL, Vallance BD, Stanley NN, et al. Atenolol and sustained release nifedipine alone and in combination in hypertension. A randomised, double-blind, crossover study. Drugs 1988; 35 (Suppl. 4): 22-6.
11. van der Veur E, ten Berge BS, Donker AJ, et al. Comparison of hydrochlorothiazide and atenolol as initial treatment in uncomplicated hypertension. Eur J Clin Pharmacol 1984; 26: 157-62.
12. Herrick AL, Waller PC, Berkin KE, et al. Comparison of enalapril and atenolol in mild to moderate hypertension. Am J Med 1989; 86: 421-6.
13. Edmonds D, Knorr M, Greminger P, et al. ACE inhibitor versus beta-blocker in the treatment of essential hypertension. Nephron 1987; 47 (Suppl. 1): 90-3.
14. Carey M, Blake S. Comparative efficacy of captopril and atenolol in moderately severe essential hypertension. Postgrad Med J 1986; 62 (Suppl. 1): 111-2.
15. Guerrero-Romero F, Rodriguez-Moran M, Sandoval-Herrrera F, et al. Prevalence of hypertension in indigenous inhabitants of traditional communities from the north of Mexico. J Hum Hypertens 2000; 14: 555-9.
16. Freytag F, Schelling A, Meinicke T, et al. Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild-to-moderate hypertension: a randomized, multicenter study. Clin Ther 2001; 23: 108-23.
17. Conway FJ, Fitzgerald JD, McAinsh J, et al. Human pharmacokinetic and pharmacodynamic studies on the atenolol (ICI 66,082), a new cardioselective beta-adrenoceptor blocking drug. Br J Clin Pharmacol 1976; 3: 267-72.
18. Neutel JM, Smith DHG. The circadian pattern of blood pressure: cardiovascular risk and therapeutic opportunities. Curr Opin Nephrol Hypertens 1997; 6: 250-6.
19. Lameijer LD, Voermans LA, Houtzagers JJ, et al. Use of fixed doses of beta blocking drugs in the treatment of hypertension. Randomised study of atenolol and penbutolol. Eur J Clin Pharmacol 1981; 21: 93-6.
20. Escudero J, Hernandez H, Martinez F. Comparative study of the antihypertensive effect of verapamil and atenolol. Am J Cardiol 1986; 57: 54D-58D.
21. McDevitt DG. Pharmacological characteristics of beta blockers and their role in clinical practice. J Cardiovasc Pharmacol 1986; 8 (Suppl. 6): S5-S11.
22. Cleophas TJ, vd Mey N, Meulen J, et al. Quality of life before and during antihypertensive treatment: a comparative study of celiprolol and atenolol. Am J Ther 1997; 4: 117-22.
23. Paran E, Anson O, Neumann L. The effects of replacing beta-blockers with an angiotensin converting enzyme inhibitor on the quality of life of hypertensive patients. Am J Hypertens 1996; 9: 1206-13.